"use client";
import React from 'react';
import Link from 'next/link';

export function BlogTirzepatideVsRetatrutide2026() {
  return (
    <div className="bg-white min-h-screen font-sans text-gray-900">
      {/* Article Header */}
      <header className="bg-gray-50 py-16 sm:py-24 border-b border-gray-200">
        <div className="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8 text-center">
          <p className="text-sm font-semibold text-blue-600 tracking-wide uppercase mb-3">Next-Gen Medications</p>
          <h1 className="text-4xl sm:text-5xl font-extrabold text-gray-900 tracking-tight mb-6">
            Tirzepatide vs. Retatrutide: The Dual vs. Triple Agonist Showdown
          </h1>
          <p className="text-xl text-gray-600 max-w-2xl mx-auto mb-8">
            As Eli Lilly's "Triple G" moves through Phase 3 clinical trials, how does retatrutide compare to the current king of weight loss, tirzepatide?
          </p>
          <div className="flex items-center justify-center space-x-4 text-sm text-gray-500">
            <span>By The Telehealth FX Clinical Team</span>
            <span>•</span>
            <span>May 2026</span>
            <span>•</span>
            <span>9 min read</span>
          </div>
        </div>
      </header>

      {/* Main Content */}
      <main className="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8 py-12">
        <article className="prose prose-lg prose-blue mx-auto max-w-none">
          <img 
            src="/assets/tirzepatide-vs-retatrutide-featured.png" 
            alt="Abstract 3D render of three interacting molecules" 
            className="w-full rounded-xl shadow-lg mb-12"
          />

          <h2>The Evolution of Incretin Therapy</h2>
          <p>
            First came <strong>Semaglutide</strong> (Wegovy), a single agonist targeting only the GLP-1 receptor. Then came <strong>Tirzepatide</strong> (Zepbound), a dual agonist targeting both GLP-1 and GIP receptors. 
          </p>
          <p>
            Now, Eli Lilly has developed <strong>Retatrutide</strong>, dubbed the "Triple G." It is a single molecule that binds to three different receptors simultaneously: GLP-1, GIP, and Glucagon (GCG). This addition of the glucagon receptor agonism fundamentally changes how the drug burns fat.
          </p>

          <div className="bg-blue-50 border-l-4 border-blue-600 p-6 my-8 rounded-r-lg">
            <h3 className="text-xl font-bold text-blue-900 mt-0 mb-2">The Glucagon Difference</h3>
            <p className="text-blue-800 mb-0">
              While GLP-1 and GIP primarily work by suppressing appetite and increasing insulin secretion, the glucagon (GCG) receptor directly stimulates the liver to burn stored fat for energy. Retatrutide doesn't just stop you from eating; it actively forces your body to burn its existing lipid stores.
            </p>
          </div>

          <h2>Clinical Trial Efficacy: A New Standard</h2>
          <p>
            In Phase 2 clinical trials, Retatrutide shattered all previous records for pharmacological weight loss.
          </p>
          <ul>
            <li><strong>Semaglutide (Wegovy):</strong> ~15% body weight loss at 68 weeks.</li>
            <li><strong>Tirzepatide (Zepbound):</strong> ~22% body weight loss at 72 weeks.</li>
            <li><strong>Retatrutide (Phase 2):</strong> <strong>24.2% body weight loss at just 48 weeks.</strong></li>
          </ul>
          <p>
            Researchers extrapolate that when the Phase 3 trials conclude at the 72-week mark, retatrutide patients may achieve nearly 30% total body weight loss, rivaling the efficacy of bariatric surgery without the scalpel.
          </p>

          <h3>The Liver Fat Miracle</h3>
          <p>
            Perhaps the most astounding finding in the retatrutide trials was its effect on Non-Alcoholic Fatty Liver Disease (NAFLD). Within 48 weeks, <strong>9 out of 10 patients on the highest dose of retatrutide completely cleared the excess fat from their liver</strong>. Tirzepatide is highly effective for fatty liver, but the glucagon agonism in retatrutide makes it uniquely powerful for hepatic clearance.
          </p>

          <table className="min-w-full divide-y divide-gray-200 my-8 shadow-sm rounded-lg overflow-hidden">
            <thead className="bg-gray-50">
              <tr>
                <th className="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider">Feature</th>
                <th className="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider">Tirzepatide (Mounjaro/Zepbound)</th>
                <th className="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider">Retatrutide (In Trials)</th>
              </tr>
            </thead>
            <tbody className="bg-white divide-y divide-gray-200">
              <tr>
                <td className="px-6 py-4 text-sm font-medium text-gray-900">Receptors Targeted</td>
                <td className="px-6 py-4 text-sm text-gray-500">GLP-1 & GIP (Dual)</td>
                <td className="px-6 py-4 text-sm text-blue-600 font-semibold">GLP-1, GIP, & Glucagon (Triple)</td>
              </tr>
              <tr>
                <td className="px-6 py-4 text-sm font-medium text-gray-900">Max Weight Loss</td>
                <td className="px-6 py-4 text-sm text-gray-500">~22% (at 72 weeks)</td>
                <td className="px-6 py-4 text-sm text-blue-600 font-semibold">24.2% (at 48 weeks)</td>
              </tr>
              <tr>
                <td className="px-6 py-4 text-sm font-medium text-gray-900">Mechanism</td>
                <td className="px-6 py-4 text-sm text-gray-500">Appetite suppression + insulin regulation</td>
                <td className="px-6 py-4 text-sm text-gray-500">Appetite suppression + direct fat oxidation</td>
              </tr>
              <tr>
                <td className="px-6 py-4 text-sm font-medium text-gray-900">Availability</td>
                <td className="px-6 py-4 text-sm text-green-600 font-semibold">FDA Approved & Available Now</td>
                <td className="px-6 py-4 text-sm text-red-600 font-semibold">Phase 3 Trials (Expected 2027)</td>
              </tr>
            </tbody>
          </table>

          <h2>Side Effects: The Trade-Off</h2>
          <p>
            Because retatrutide hits three receptors, its side effect profile is slightly different. While gastrointestinal issues (nausea, diarrhea) are similar to tirzepatide, retatrutide patients in early trials reported a higher incidence of <strong>cardiac arrhythmias (elevated heart rate)</strong> and hyperesthesia (skin sensitivity).
          </p>
          <p>
            The glucagon receptor increases metabolic expenditure, which naturally elevates the resting heart rate. The FDA will closely monitor this cardiovascular data during Phase 3 trials.
          </p>

          <h2>Should You Wait for Retatrutide?</h2>
          <p>
            No. Retatrutide is not expected to hit pharmacy shelves until 2027 at the earliest. Obesity is a progressive disease. Waiting years for a "better" drug allows metabolic damage to accumulate. Tirzepatide is currently the most powerful, FDA-approved weight loss medication on the planet, and it is available right now.
          </p>

          <div className="bg-gray-50 p-8 rounded-xl mt-12 border border-gray-200 text-center">
            <h3 className="text-2xl font-bold text-gray-900 mb-4 mt-0">Don't Wait to Change Your Health</h3>
            <p className="text-gray-600 mb-6">
              Tirzepatide is the gold standard of current obesity medicine, available immediately. Telehealth FX provides access to both brand-name and compounded Tirzepatide at transparent prices.
            </p>
            <Link href="https://go.telehealthfx.com/start" className="inline-block bg-blue-600 text-white font-bold py-3 px-8 rounded-full hover:bg-blue-700 transition duration-300">
              Start Tirzepatide Today
            </Link>
          </div>
        </article>
      </main>
    </div>
  );
}
